RXRX241227C17500
- 0.05
- 0.000.00%
Recursion Pharmaceuticals Newsroom
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Express News | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Express News | Recursion Pharmaceuticals Inc - Registering for Resale 3.5 Mln Shares of Class a Common Stock
Express News | Recursion Pharmaceuticals Inc - Files Prospectus Supplement
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals' (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials
Hold Rating for Recursion Pharmaceuticals Amid Early Efficacy Signals and Financial Concerns
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $12
Cautious Optimism for Recursion Pharmaceuticals Amid Promising Safety Profile and Upcoming Milestones
10 Health Care Stocks With Whale Alerts In Today's Session
What's Going On With Recursion Pharmaceuticals Stock?
Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated
Express News | Recursion Pharmaceuticals Inc: Plans to Continue Monotherapy Dose Escalation and Initiate Combination Studies in 1H 2025